Two studies have shown that cultured leukemia cells from pediatric MLL-rearranged ALLs are more sensitive to the cytotoxicity of FLT3 inhibitors, PKC412 or CEP-701, than ALL cells with germline MLL[14], [15] expressing lower levels of FLT3. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.